Reaffirms Q4 2022 Upneeq Net Product Sales Guidance Of $20 To $25 Mln
07/07/2022 13:02
July 7 (Reuters) - RVL Pharmaceuticals PLC RVLP.O :
* RVL PHARMACEUTICALS PLC - REAFFIRMS Q4 2022 UPNEEQ NET PRODUCT SALES
GUIDANCE OF
$20 TO $25 MILLION
* RVL PHARMACEUTICALS - EXPECTS Q2 2022 PRELIMINARY UPNEEQ NET PRODUCT SALES
OF
ABOUT $8.4 MILLION, REPRESENTING AN INCREASE OF 42% FROM Q1 2022
* RVL PHARMACEUTICALS - FROM FEBRUARY THROUGH JUNE OF 2022 IT HAD RECEIVED
ORDERS
FROM ABOUT 2,200 CUMULATIVE UNIQUE MEDICAL AESTHETICS PRACTICES
Source text for Eikon: ID:nGNX9kpCjs
Further company coverage: RVLP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RVL Pharmaceuticals
See all newsBrief: RVL Pharmaceuticals Says High Court Of Ireland Made A Winding Up Order In Respect Of Co On Feb 12
Brief: RVL Pharmaceuticals Says Co Issued Petition In Central Office Of High Court In Ireland To Wind Up Company
Brief: RVL Completes Financial Restructuring
Brief: Rvl Pharmaceuticals PLC Received Delisting Notice From Listing Qualifications Department Of Nasdaq Stock Market Llc
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius